Replies to post #183097 on Biotech Values

[jbog]

Why would anyone want to own MYL in the next year or so

The current management leaders have been with Myl for many years and have supplied their investors with above average returns for many, many years. (5yr-200%)

I don't see why I would question their ability at this point.

P.S. I would like to see a return of the div eventually.

[jbog]

Myland hits all time high today. With 2015 earning projections as high as $4.25 (2014 $2.35) it certainly has room to go.

Maybe Abbott should hold on to their position for awhile, if not the street will absorb their shares without a hitch.

[jbog]

Mylan N.V. (NASDAQ: MYL) today announced the underwritten public offering (the "Offering") of 35,000,000 ordinary shares held by certain subsidiaries of Abbott Laboratories ("Abbott"). Abbott also has granted the underwriters an option to purchase an additional 5,250,000 ordinary shares. Mylan will not sell any ordinary shares in the Offering and will not receive any of the proceeds from the Offering. The 35,000,000 ordinary shares being sold (or 40,250,000 ordinary shares if the underwriters' option is exercised) represent 31.8% (or 36.6% if the option is exercised) of the 110,000,000 ordinary shares currently owned by Abbott.

Morgan Stanley & Co. LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the Offering. A shelf registration statement (including prospectus) relating to the ordinary shares to be sold in the Offering is effective with the Securities and Exchange Commission (the "SEC"). Before you invest, you should read the prospectus and any documents filed with the SEC for more complete information about the Company and this Offering. Copies of these documents are available for free on the SEC's website at www.sec.gov. The Offering may be made only by means of a prospectus supplement and a prospectus. A copy of the prospectus supplement and the prospectus relating to the Offering can be obtained from: (i) Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department and (ii) Goldman, Sachs & Co., 200 West Street, New York, NY 10282, Attn: Prospectus Department, toll free at [phone] or at [e-mail].

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities mentioned in this press release in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Offering will only be made by means of the prospectus and the prospectus supplement.

Mylan N.V. is considered the successor to Mylan Inc. for certain purposes under the Securities Act of 1933 and the Securities Exchange Act of 1934.

[jbog]

Why would anyone want to own MYL in the next year or so (unless you think they will get FDA approval for generic Copaxone)? After the ‘spinversion’ (#msg-107440341), ABT will own 22% of MYL and plans to divest its MYL shares fairly quickly, which will put a lot of pressure on MYL’s share price.

Nice 40% return in 6 months.